Back to News
Top StoriesMarketWatch3h ago

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Read Full Article on MarketWatch

MENTIONED STOCKS

Content sourced from MarketWatch. Not financial advice.